Acadia Healthcare Company, Inc.

source: coverage-next-full ticker: ACHC step: "01" title: Business Model & Overview created: 2026-06-03

Step 01 — Business Model & Overview: ACHC (Acadia Healthcare Company, Inc.)

[S1] Business Model Summary

Acadia Healthcare is the largest publicly traded pure-play behavioral health facility operator in the United States. Its economic model is straightforward: own or lease inpatient psychiatric beds and outpatient program slots, staff them with licensed clinicians, and generate revenue from public and private payors (Medicaid, Medicare, commercial insurance) on a per-diem or per-service basis.

The business is capital-intensive (facilities + equipment), labor-intensive (clinicians and nursing staff ~53% of revenue), and heavily regulated (state licensing, CON laws, federal reimbursement rules). The moat sources — if durable — are geographic network density, CON barriers in select markets, brand/referral relationships with hospitals and payers, and scale in procurement and staffing.

Sources: [S1] 10-K FY2024; StockAnalysis summary (2026-06-03)

[S2] Value-Chain Layer Map

Layer                       ACHC's Role
─────────────────────────────────────────────────────────────────
DEMAND GENERATION           Referrals from hospital ERs, PCPs,
                            payers, community mental health orgs,
                            self-referrals. ACHC invests in
                            referral relationships + care coordination.

FACILITY OWNERSHIP          Own ~262 facilities (~11,850 beds).
                            Mix of owned real estate + lease.
                            Capital-intensive: Net PP&E $3.24B (FY2025).

CLINICAL SERVICE DELIVERY   ACHC employs/contracts psychiatrists,
                            psychologists, nurses, counselors,
                            behavioral health techs (~23,000 employees).
                            Service types: inpatient, PHP, IOP, MAT/CTC,
                            eating disorders, youth programs.

PAYOR CONTRACTING           Contracts with state Medicaid programs
                            (~57% of revenue), commercial MCOs (~28%),
                            Medicare (~15%). Rate negotiations are
                            recurring and material to margin.

BACK-OFFICE / ADMIN         Centralized billing, compliance, credentialing,
                            HR, supply chain from Franklin TN HQ.
                            Scale benefit: >$3B revenue creates leverage
                            vs. smaller independent operators.

Sources: [S2] 10-K FY2024 business description; proxy filings

[S3] Service Line Architecture

Inpatient Psychiatric Hospitals & Residential Treatment Centers (est. ~55-60% of revenue)

• Acute inpatient psychiatric care for adults and youth
• High-acuity, typically 7-30 day length of stay
• Highest reimbursement per day; most capacity-constrained service line
• Adding ~600-800 beds/year predominantly in this category

Comprehensive Treatment Centers / CTCs (~15-20% of revenue est.)

• Medication-Assisted Treatment (MAT) for opioid use disorder
• Outpatient model; daily buprenorphine/methadone dispensing
• Opened 9 new CTCs in FY2024; heavily Medicaid-reimbursed
• Subject to SAMHSA/DEA regulatory oversight in addition to state licensing

Partial Hospitalization (PHP) & Intensive Outpatient (IOP)

• Step-down from inpatient; 3-6 hours/day treatment
• Growing as payors push earlier discharge from inpatient settings

Eating Disorder Residential & Outpatient

• Residential (24-hour care) and day-treatment programs
• Primarily commercial insurance; higher revenue per day than general psych

Youth & Adolescent Programs

• Residential treatment centers for youth; significant Medicaid exposure
• Subject to heightened regulatory scrutiny (youth facility oversight)

Sources: [S3] 10-K FY2024; competitive landscape analysis

[S4] Revenue Model — Economic Mechanics

Core revenue equation:

Revenue = Σ (Beds × Utilization Rate × Net Revenue Per Patient Day)
         + Outpatient visits × Net Revenue Per Visit

Drivers of same-facility revenue growth (FY2024: +7.6%):

• Volume: Same-facility patient days +3.2% (admissions +1.3%, length of stay slightly up)
• Rate: Same-facility revenue per patient day +4.3% (Medicaid rate updates, commercial mix improvement)

New facility revenue contribution: Beds added in prior years ramp over 24-36 months; new facilities are dilutive to margins initially, then accretive as census fills.

Payor mix sensitivity:

• Medicaid: ~57% of revenue; state-set rates; ~70-80% of Medicare rates; highly stable volume but low rate growth
• Commercial: ~28%; best rates; MCO contracting determines net realization
• Medicare: ~15%; set by CMS; 14.6% cut to key psych CPT codes in 2025 is a headwind

Sources: [S4] 10-K FY2024 MD&A; consensus data (2026-06-03)

[S5] Growth Strategy — Five Pathways

ACHC's stated growth strategy operates through five pathways [S5]:

1. Bed additions at existing facilities — lowest cost, fastest to revenue ($300-400K/bed)
2. Joint venture partnerships — partner with health systems (risk-sharing, referral access)
3. De novo facility openings — greenfield; highest cost ($1M+/bed), 24-36 month ramp
4. Acquisitions — bolt-on; slowed significantly since 2020; FY2024 acquisition: Turning Point Centers (76 beds, $54M)
5. Continuum of care expansion — PHP/IOP alongside inpatient; CTCs in new markets

FY2024 execution: Added 776 beds total (312 expansions + 464 new openings), 9 new CTCs, 1 acquisition. FY2025 CapEx: $572M (moderated from $690M peak) FY2026 CapEx guidance: ~$450-570M (management targeting decline)

Sources: [S5] 10-K FY2024 business description; investor presentation 2024

[S6] Management & Ownership

Leadership (as of mid-2026):

• CEO: Christopher Osteen (appointed ~2025/2026, previously Kindred Healthcare); replacing Debbie Osteen (departed)
• CFO: David Dixon (base salary $690K; key continuity executive)
• Other NEOs: Farley ($550K base)

Ownership:

• Wellington Management: 12.76% (largest holder; active value investor)
• BlackRock: ~5% (passive)
• Vanguard: ~5.51% (passive, 5,079,563 shares per April 2026 13G)
• Short interest: 24.9% of float (22.6M shares) — significant bear thesis in the market
• No insider open-market buying during ~70-85% drawdown (2023-early 2026); management blackout likely due to DOJ investigation

Sources: [S6] Governance file; StockAnalysis ownership data; proxy DEF 14A 2025

[S7] Competitive Position Summary

ACHC holds the #1 pure-play US behavioral health scale position, though Universal Health Services (UHS) — a diversified hospital operator — has a larger absolute behavioral bed count. Key competitive differentiators:

• Pure-play focus: 100% behavioral health vs. UHS (behavioral is ~50% of UHS)
• Geographic breadth: 39 states provides national payor contracting leverage
• CON barriers: Licensed inpatient psych beds in CON states are effectively non-replicable

Key vulnerabilities:

• Medicaid concentration: 57% exposure creates political/budget risk
• Labor: Psychiatrist shortage is industry-wide; ACHC's scale helps but doesn't eliminate
• DOJ overhang: Civil investigation into SUD billing practices at certain facilities

Sources: [S7] Competitive landscape analysis; 10-K FY2024

Source Index

source: coverage-next-full ticker: ACHC step: "04" title: Financial Quality & Adversarial Sweep created: 2026-06-03

Step 04 — Financial Quality & Adversarial Sweep: ACHC

[S1] Statement Quality Assessment

Adjustments Required for Comparability

ACHC's GAAP financials require several adjustments for clean trend analysis [S1]:

Clean adjusted metrics (FY2022-FY2025):

*FY2024 adj. OCF = reported $130M + ~$300M Desert Hills payments restored **FY2025 OCF of $132M appears to be without major one-time items; CapEx was $572M

Sources: [S1] XBRL data; 10-K FY2024 MD&A; StockAnalysis; consensus

Revenue Recognition Quality

• Revenue recognized on an accrual basis as services delivered; per-diem and fee-for-service models are straightforward
• Contractual allowances: ACHC books gross charges then nets against expected payor reimbursement. The net realization is what's reported. No known channel stuffing or revenue manipulation concerns.
• Accounts receivable DSO of 43 days (FY2024) is reasonable for a diversified government + commercial payor mix. Slight improvement from 45 days in FY2023. No significant DSO deterioration trend.

Sources: [S1] 10-K FY2024 revenue recognition accounting policy; MD&A

[S2] Balance Sheet Quality

Goodwill & Intangibles

*FY2025 goodwill significantly reduced after $1.5B impairment.

Goodwill impairment in FY2025 confirms that prior M&A (2012-2019 acquisition phase) was done at prices that did not generate adequate returns at current earnings levels. This is a red flag for prior capital allocation discipline but does not directly impair future operations.

Post-impairment goodwill balance is more defensible at current EBITDA levels.

Sources: [S2] StockAnalysis balance sheet; 10-K FY2024/FY2025

Debt Structure & Leverage

FY2026 leverage target: 3.9-4.2x per company guidance — implies minimal deleveraging even at $593M EBITDA midpoint. Debt service of ~$200M+/year (interest + amortization) is manageable but leaves limited FCF headroom.

Credit facility: Post-2025 refinancing (prior March 2026 maturity resolved). Specific new terms not confirmed in cached data, but company disclosed refinancing in 2025 filings.

Sources: [S2] StockAnalysis balance sheet; XBRL; consensus

[S3] Cash Flow Quality

Operating Cash Flow normalization:

True normalized FCF burn FY2024-2025: ~($260M) to ($440M)/year during peak expansion.

Maintenance CapEx: ~$104M/year (FY2024 disclosure); ~3.3% of revenue. Economically, expansion CapEx is voluntary (growth investment), not required to maintain the base business. This is an important distinction for FCF-based valuation — ACHC's base business generates substantial OCF; the FCF burn is a growth reinvestment choice.

FCF recovery path: Management guidance calls for FCF positive by end-2026. CapEx guidance $450-570M for FY2026 vs. $572M in FY2025. If adj. EBITDA holds at $590M and CapEx declines to $450M, the math requires D&A-adjusted OCF of ~$600M+ to get to positive FCF. This requires: (a) no additional working capital drag and (b) no further settlement payments.

Sources: [S3] XBRL cash flow; 10-K FY2024 MD&A; investor presentation 2024; consensus

[S4] Adversarial Research Sweep

Note: Transcript analysis was not performed; adversarial research conducted via SEC disclosure review, press release analysis, and web search for third-party investigations and short seller research.

Finding 1: DOJ Civil Investigation (Material)

• Acadia disclosed a DOJ Civil Division investigation focused on billing practices at certain substance use disorder (SUD) treatment facilities (CTCs / opioid treatment programs)
• Investigation is civil, not criminal (as of most recent disclosure); subpoenas issued
• Magnitude of potential settlement: unquantified in filings; precedent cases (Sheppard Pratt: $15M; large behavioral chains: $50-300M range)
• Risk assessment: Real and material; creates uncertainty on balance sheet and M&A optionality. The DOJ investigation also likely explains the absence of insider open-market buying during the 70-85% stock drawdown.
• Source: 8-K disclosures; risk factor in 10-K FY2024

Finding 2: Desert Hills Litigation (Resolved Financially, Ongoing Reputationally)

• Desert Hills Recovery Center (Arizona facility) was involved in patient safety incidents and insurance fraud allegations (billing for services not rendered, patient welfare violations)
• $394.2M settlement (FY2023 charge; cash paid in FY2024)
• Desert Hills was operated under ACHC management; this is a quality-of-care and billing compliance red flag
• Post-settlement, ACHC implemented compliance program enhancements
• Source: 10-K FY2023/FY2024; press reporting

Finding 3: Goodwill Impairment ($1.5B, FY2025)

• Non-cash; does not affect operations or liquidity directly
• However, it confirms prior acquisitions were executed at prices not justified by subsequent earnings power
• Raises questions about ROIC discipline in the acquisition phase (2012-2019)
• Management response: pivot away from acquisitions toward de novo + JV growth (lower purchase-price risk)
• Source: StockAnalysis; consensus data (Q4 FY2025 results)

Finding 4: High Short Interest (24.9% of Float)

• 22.6M shares short (8.2 days to cover) suggests significant bearish conviction from professional investors
• Short thesis likely focuses on: DOJ settlement risk, Medicaid rate pressure, leverage trajectory, FCF negativity
• Short interest peaked ~35.9% in February 2026 and has moderated (stock up from $11.43 low to $24.42)
• Source: StockAnalysis ownership data; consensus

Finding 5: Labor Inflation / Staffing Challenges

• Behavioral health clinician shortage is acute; travel nurses and contract staff inflate SWB costs
• SWB at 53.6% of revenue is high; no meaningful improvement in this ratio FY2022-FY2024
• Source: 10-K FY2024 risk factors; industry analysis

Finding 6: CEO Transition

• Christopher Osteen installed as CEO (2025/2026) replacing prior CEO; significant management change during critical execution phase
• New CEO background (Kindred Healthcare) is relevant (post-acute/behavioral); not an external hire without sector experience
• Source: Proxy; press research; investor presentation

Finding 7: No Known Short-Seller Reports

• No high-profile short-seller reports (Muddy Waters, Hindenburg, etc.) targeting ACHC found in research
• The DOJ investigation and Desert Hills are known to the market and already partially priced in

Overall Adversarial Assessment: The bear case has merit on DOJ risk, leverage, and payor pressure — but the Desert Hills issue is largely resolved financially, the goodwill impairment is non-cash, and the DOJ investigation appears civil in scope. The fundamental revenue stream (behavioral health inpatient) is structurally sound. The primary financial risk is FCF negativity persisting beyond 2026 if CapEx does not normalize or if EBITDA disappoints.

Sources: [S4] 10-K FY2024 risk factors; 8-K disclosures; StockAnalysis; web research

Source Index